Abstracts Archive - Page 2398 of 2607 - ACR Meeting Abstracts

Abstract Number: 480 • 2013 ACR/ARHP Annual Meeting
Levels Of Circulating Mirnas Before and After 12 Months Therapy With Dmards In Patients With Early Rheumatoid Arthritis
Mária Filková¹, Borbala Aradi², Ladislav Senolt³, Klara Prajzlerova⁴, Serena Vettori², Herman F. Mann⁵, Jiri Vencovsky⁴, K. Pavelka⁶, Beat A. Michel⁷, Renate E Gay², Steffen Gay² and Astrid Jüngel², ¹Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, ²Center of Experimental Rheumatology, University Hospital Zurich and Zurich Center of Integrative Human Physiology (ZIHP), Zurich, Switzerland, ³Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ⁴Institute of Rheumatology, Department of Clinical and Experimental Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ⁵Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Prague, Czech Republic, ⁶Department of Clinical and Experimental Rheumatology, Charles University, Prague, Czech Republic, ⁷Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland
Background/Purpose: The altered expression of cellular miRNAs in the immune and resident cells involved in the pathogenesis of rheumatoid arthritis (RA) has been shown to…
Abstract Number: 481 • 2013 ACR/ARHP Annual Meeting
Down-Titration of Biological Therapies In Rheumatoid Arthritis In Daily Clinical Practice
Miguel Arredondo¹, Iciar Cañamares², Esther Ramírez-Herráiz², Isidoro Gonzalez-Alvaro³, Alberto Garcia-Vadillo³, Alberto Morell¹, Rosario Garcia-Vicuña⁴ and Jose María Alvaro-Gracia⁵, ¹Unidad de Terapias Biológicas, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ²Servicio de Farmacia, Hospital Universitario de La Princesa, Madrid, Spain, ³Servicio de Reumatología, Hospital Universitario de La Princesa, Madrid, Spain, ⁴Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ⁵Unidad de Terapias Biológicas. Servicio de Reumatología, Hospital Universitario de La Princesa, Madrid, Spain
Background/Purpose: One of the limiting factors for the use of biological therapies (BT) is cost. For this reason, the development of cost optimization strategies without…
Abstract Number: 482 • 2013 ACR/ARHP Annual Meeting
Methotrexate Use At Infliximab Initiation and Impact On Treatment Outcomes: An Analysis From A Canadian Registry
Denis Choquette¹, J. Carter Thorne², John T. Kelsall³, Michel Zummer⁴, Michael Starr⁵, Maqbool K. Sheriff⁶, William G. Bensen⁷, Andrew Chow⁸, Philip Baer⁹, Emmanouil Rampakakis¹⁰, John S. Sampalis¹⁰, Francois Nantel¹¹, Allen J. Lehman¹², Susan M. Otawa¹² and May Shawi¹³, ¹Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ²Southlake Regional Health Centre, Newmarket, ON, Canada, ³Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, Canada, ⁴Rheumatology, Ch Maisonneuve-Rosemont, Montreal, QC, Canada, ⁵Montreal General Hospital, Montreal, QC, Canada, ⁶Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁷Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, ⁸University of Toronto, McMaster University, Credit Valley Rheumatology, Mississauga, ON, Canada, ⁹Private Practice, Scarborough, ON, Canada, ¹⁰JSS Medical Research, Montreal, QC, Canada, ¹¹Janssen Inc., Toronto, ON, Canada, ¹²Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹³Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada
Background/Purpose: Clinical trials of anti-TNF therapies have shown that concurrent methotrexate (MTX) therapy enhances the efficacy of infliximab (IFX)1. Data on the benefits of combination…
Abstract Number: 483 • 2013 ACR/ARHP Annual Meeting
Adalimumab and Methotrexate Pharmacokinetics Following Combination Therapy With Different Methotrexate Doses in Methotrexate and Biologic-Naïve Rheumatoid Arthritis Patients: Concerto Study
Sandra L Goss¹, Cheri E Klein¹, Hartmut Kupper², Gerd Burmester³ and Walid Awni¹, ¹AbbVie Inc., North Chicago, IL, ²AbbVie Deutschland GmBH & Co. KG, Ludwigshafen, Germany, ³Department of Rheumatology & Clinical Immunology, Charité-Universitätsmedizin Berlin, Free University and Humboldt University of Berlin, Berlin, Germany
Background/Purpose: Higher exposure and lower immunogenicity rates have been observed for adalimumab when co-administered with methotrexate (MTX) compared to adalimumab monotherapy. The CONCERTO study was…
Abstract Number: 484 • 2013 ACR/ARHP Annual Meeting
Response To Biologic Disease-Modifying Anti-Rheumatic Drugs After Discontinuation Of Anti-Tumor Necrosis Factor Alpha Agents In Rheumatoid Arthritis Patients
Eric Elkin¹, Max I. Hamburger², Tripthi Kamath³, Sarika Ogale³, Adam Turpcu³, Jae Oh⁴, Kristin King⁴, Monarch Shah¹ and Martin J. Bergman⁵, ¹ICON Clinical Research, San Francisco, CA, ²Rheumatology Associates, Melville, NY, ³Genentech, South San Francisco, CA, ⁴ICON Late Phase and Outcomes Research, San Francisco, CA, ⁵Taylor Hospital, Ridley Park, PA
Background/Purpose: Rheumatoid arthritis (RA) patients who have failed an anti-TNF agent as their first biologic agent have the option of switching to a second aTNF…
Abstract Number: 486 • 2013 ACR/ARHP Annual Meeting
Safety Of Biologic Therapy In Veterans With Rheumatoid Arthritis and Chronic Hepatitis B Infection
Jeffrey R. Curtis¹, Mary J. Burton², Shuo Yang³, Lang Chen⁴, Ted R. Mikuls⁵, Kevin L. Winthrop⁶ and John Baddley⁷, ¹University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Birmingham, AL, ²VA Hospital, Jackson, MS, ³Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁶Dept of Infectious Disease, Oregon Health & Science University, Portland, OR, ⁷Medicine, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Among patients with rheumatoid arthritis and hepatitis B infection, the impact of biologic therapy on hepatotoxicity has received limited study. Methods: Using 1997-2011 national…
Abstract Number: 487 • 2013 ACR/ARHP Annual Meeting
The Cost Savings Associated With a Departmental Etanercept Dose Reduction Pathway For Patients With Rheumatic Diseases and Maintained Low Disease Activity
Richard CJ Campbell¹, Emma Sanders¹, Francesca Leone¹, Emma Gilgeours¹, Margaret Sibley¹ and Patrick D. Kiely², ¹Rheumatology, St George's Hospital, London, United Kingdom, ²Rheumatology Dept, St George's Hospital, London, United Kingdom
Background/Purpose: Clinical trials have previously demonstrated that it is safe and effective for some rheumatoid arthritis (RA) patients with low disease activity on full dose…
Abstract Number: 488 • 2013 ACR/ARHP Annual Meeting
The Effect Of Methotrexate On Adalimumab Pharmacokinetics: Pooled Analysis Of Adalimumab Pharmacokinetics In Patients With Rheumatoid Arthritis After Subcutaneous Administration
Walid Awni¹, Sabine Pilari², Ghada Ahmed³ and Peter Noertersheuser², ¹AbbVie Inc., North Chicago, IL, ²AbbVie Deutschland GmbH & Co KG, Ludwigshafen, Germany, ³AbbVie, North Chicago, IL
Background/Purpose: Co-administration of methotrexate (MTX) has a significant effect on the pharmacokinetics (PK) of adalimumab (ADAL). MTX may impact the PK of other drugs by…
Abstract Number: 489 • 2013 ACR/ARHP Annual Meeting
Combining Methotrexate To Etanercept Does Not Improve Its Retention Rate In Rheumatoid Arthritis Patients When Compared To Etanercept Monotherapy. A Report From The Rhumadata® Clinical Data Base and Registry
Denis Choquette¹, Louis Bessette², Boulos Haraoui¹, Diane Sauvageau³, Jean Pierre Pelletier¹, Jean-Pierre Raynauld³, Edith Villeneuve³ and Louis Coupal¹, ¹Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ²Centre Hospitalier Universitaire de Québec, pavillon CHUL, Sainte-Foy, QC, Canada, ³Rheumatology, Institut de Rhumatologie de Montréal, Montreal, QC, Canada
Background/Purpose: Etanercept (ETA) has demonstrated good retention in both mono and combination therapy in clinical trials of rheumatoid arthritis patients followed over short observation periods…
Abstract Number: 490 • 2013 ACR/ARHP Annual Meeting
Does Low Disease Activity At Six Months Predict Remission At 12 Months In Rheumatoid Arthritis Patients Treated With Biologics In a Real–World Setting?
Philip Baer¹, William G. Bensen², Andrew Chow³, Rafat Y. Faraawi^4,5, Denis Choquette⁶, Isabelle Fortin⁷, John T. Kelsall⁸, Dalton E. Sholter⁹, Emmanouil Rampakakis^10,11, John S. Sampalis^10,11, Francois Nantel¹², Allen J. Lehman¹³, May Shawi¹⁴ and Susan M. Otawa¹³, ¹Private Practice, Scarborough, ON, Canada, ²Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, ³University of Toronto, McMaster University, Credit Valley Rheumatology, Mississauga, ON, Canada, ⁴Rheumatologist, KW Musculoskeletal Research Inc., Kitchener, ON, Canada, ⁵McMaster University, Hamilton, ON, Canada, ⁶Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ⁷Centre de rhumatologie de l'est du Québec (CREQ), Rimouski, QC, Canada, ⁸Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, Canada, ⁹Rheumatology Associates, Edmonton, AB, Canada, ¹⁰JSS Medical Research, Montreal, QC, Canada, ¹¹Jewish General Hospital, McGill University, Montreal, QC, Canada, ¹²Janssen Inc., Toronto, ON, Canada, ¹³Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹⁴Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada
Background/Purpose: Remission is considered the treatment goal in the management of patients with rheumatoid arthritis (RA). The objective of this analysis was to determine if…
Abstract Number: 491 • 2013 ACR/ARHP Annual Meeting
Infection Risk Among Patients Receiving Concurrent Denosumab and Biologic Or Non-Biologic DMARD Therapy: An Analysis Of The Consortium Of Rheumatology Researchers Of North America (CORRONA) Registry
Vance J. Bray¹, Adam W. Bagley², Sterling G. West³, Carol J. Etzel⁴, Joel M. Kremer⁵ and Jason R. Kolfenbach⁶, ¹Denver Arthritis Clinic, Denver, CO, ²Internal Medicine, University of Colorado School of Medicine, Aurora, CO, ³Rheumatology, University of Colorado School of Medicine, Aurora, CO, ⁴Department of Epidemiology, UT MD Anderson, Houston, TX, ⁵Medicine, Albany Medical College and the Center for Rheumatology, Albany, NY, ⁶Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO
Background/Purpose: RANKL is a cytokine member of the tumor necrosis family that mediates osteoclastic bone resorption. Denosumab prevents RANKL from activating RANK on the cell…
Abstract Number: 492 • 2013 ACR/ARHP Annual Meeting
Distinction Between Glucocorticoid-Responders and Non-Responders In Rheumatoid Arthritis: A New Role For Endoplasmic Reticulum Aminopeptidase 2
Ruth Fritsch-Stork¹, Sandra Cardoso¹, Jasper Broen¹, Marian Groot-Koerkamp², Arno Concepcion¹, Floris Lafeber¹ and Johannes W.J. Bijlsma¹, ¹Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Molecular Cancer Research, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Glucocorticoids (GC) have been a cornerstone of Rheumatoid arthritis (RA)-therapy for the last decades. However, about a third of RA-patients do not respond adequately.…
Abstract Number: 493 • 2013 ACR/ARHP Annual Meeting
A Real-World Risk Analysis Of Biological Treatment (Adalimumab and Etanercep) In Country With High Prevalence Of Tuberculosis and Hepatitis B/C
Ying-Ming Chiu¹, Chao-Hsiung Tang², Sheng-Tzu Hung³, Ya-Wen Yang⁴, Chi-Hui Fang⁴ and Hsiao-Yi Lin⁵, ¹Changhua Christian Hospital, Changhua City, Taiwan, ²Taipei Medical University, Taipei, Taiwan, ³Formosa Biomedical Technology Corp., Taipei, Taiwan, ⁴Pfizer Limited, Taipei, Taiwan, ⁵Immunology and Rheumatology, Dept of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
Background/Purpose: Biologics have been widely utilized in many rheumatic diseases. Risks associated with the use of biological treatments are revealed in many published studies. Nevertheless,…
Abstract Number: 494 • 2013 ACR/ARHP Annual Meeting
Autoantibody Profiles Predict Responsiveness To Methotrexate and Anti-TNF Therapy In Early Rheumatoid Arthritis
Petra Budde¹, Angelika Lueking¹, Carmen Theek¹, Peter Schulz-Knappe¹, Jacqueline Detert², Gerd Burmester³ and Matthias Schneider⁴, ¹Protagen AG, Dortmund, Germany, ²Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Berlin, Germany, ³Department of Rheumatology & Clinical Immunology, Charité-Universitätsmedizin Berlin, Free University and Humboldt University of Berlin, Berlin, Germany, ⁴Department of Endocrinology, Diabetes and Rheumatology, Heinrich-Heine-University, Duesseldorf, Germany
Background/Purpose: Novel therapeutic concepts in early rheumatoid arthritis (ERA) are aiming for an early intervention and effective control of disease activity reaching remission. Most current…
Abstract Number: 495 • 2013 ACR/ARHP Annual Meeting
The Impact Of Inadequate Response To Prior Biologic Agents On Abatacept Drug Retention In Rheumatoid Arthritis Patients. A Pan-European Analysis Of RA Registries
Axel Finckh¹, Florenzo Iannone², Juan Gomez Reino³, David Neto⁴, Elisabeth Lie⁵, Piet van Riel⁶, Merete Lund Hetland⁷, Karel Pavelka⁸, Carl Turesson⁹, Xavier Mariette¹⁰ and Jacques-Eric Gottenberg¹¹, ¹Department of Medical Specialities, University of Geneva, Geneva, Switzerland, ²D.I.M.I.M.P, Rheumatology Unit - University of Bari, Bari, Italy, ³Rheumatology Department, Hospital Clínico de Santiago, Santiago de Compostela, Spain, ⁴Rheumatology, University of Geneva, Geneva, Switzerland, ⁵Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁶Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁷Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, The Danish Rheumatologic Database (DANBIO), Glostrup Hospital., Copenhagen, Denmark, ⁸Department of Clinical and Experimental Rheumatology, Charles University, Prague, Czech Republic, ⁹Lund University, Malmö, Sweden, ¹⁰Paris-Sud University, Paris, France, ¹¹Division of Rheumatology, University Hospital of Strasbourg, Strasbourg, France
Background/Purpose: In rheumatoid arthritis (RA), abatacept (ABA) may be used in biologic naïve patients (pts) or after failure to an anti-TNF or other biologic agents…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].